Prof Brian Van Tine speaks to ecancer in an online interview for the virtual ASCO 2021 meeting about the APROMISS trial.
This was a phase III trial evaluating AL3818 (catequentinib, anlotinib) hydrochloride monotherapy compared with dacarbazine in subjects with metastatic or advanced synovial sarcoma.
He reports that the progression free survival for catequentinib bettered dacarbazine with the safety profile comparable to similar drugs in the field.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.